HU-Go App for Sickle Cell Disease Adherence

Recruiting in Palo Alto (17 mi)

Overseen bySherif M. Badawy, MD, MS

Age: < 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago

No Placebo Group

Trial Summary

What is the purpose of this trial?

The primary objective of this study is to better understand factors contributing to variations in hydroxyurea (HU) adherence behavior in adolescents and young adults (AYA) with sickle cell disease (SCD). To meet this objective, the researchers will conduct a prospective cohort study to determine the longitudinal relationship between HU adherence and health-related quality of life (HRQOL) overtime among AYA with SCD. The long-term goal of this research is to promote medication adherence behavior and improve health outcomes in AYA with SCD.

Research Team

Sherif M. Badawy, MD, MS

Principal Investigator

Ann & Robert H Lurie Children's Hospital of Chicago

Eligibility Criteria

This trial is for young individuals aged 12-21 with any type of sickle cell disease who have been taking hydroxyurea consistently for at least 2 months. They must own or have access to a smartphone. Parents of eligible patients can also participate. Those recently hospitalized within the past week cannot join.

Inclusion Criteria

Parents of patients that meet the eligibility criteria and are enrolled in the study will be included

I am between 12 and 21 years old.

I have a type of sickle cell disease.

See 2 more

Exclusion Criteria

Patients with recent hospitalizations within the past 7 days

Treatment Details

Interventions

HU-Go app (Behavioural Intervention)

Trial OverviewThe study is testing the 'HU-Go app' and its impact on medication adherence over time in adolescents and young adults with sickle cell disease. It aims to understand how using this app affects their health-related quality of life and habits related to taking hydroxyurea.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: HU-Go app intervention armExperimental Treatment1 Intervention

Participants will use the HU-Go app intervention arm for 12 months.